Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: J Med Virol. 2017 May 23;89(9):1620–1628. doi: 10.1002/jmv.24809

Figure 3. SB 9200 shows activity against HCV derived from patients who have relapsed after IFN based therapy.

Figure 3

Capture fusion assay was performed with sera from patients who had relapsed after IFN based therapy. Comparison of the SB 9200 IC50 between treatment naïve (g1 n=5 and g3 n=7) and treatment experienced (g1 n=3 and g3 n=4 ) revealed no significant difference between the groups.